Biotechnology Assets SA
MAD:BST
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.26
0.432
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biotechnology Assets SA
Biotechnology Assets SA
Other Current Liabilities
Biotechnology Assets SA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotechnology Assets SA
MAD:BST
|
Other Current Liabilities
€1.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Grifols SA
MAD:GRF
|
Other Current Liabilities
€283.8m
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Oryzon Genomics SA
MAD:ORY
|
Other Current Liabilities
€2.2m
|
CAGR 3-Years
18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Pharma Mar SA
MAD:PHM
|
Other Current Liabilities
€43m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
31%
|
CAGR 10-Years
16%
|
|
Biotechnology Assets SA
Glance View
Biotechnology Assets SA operates as a biopharmaceutical company. The company is headquartered in Jerez De La Frontera, Cadiz and currently employs 32 full-time employees. The company went IPO on 2011-06-14. The Firm’s main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.
See Also
What is Biotechnology Assets SA's Other Current Liabilities?
Other Current Liabilities
1.9m
EUR
Based on the financial report for Jun 30, 2024, Biotechnology Assets SA's Other Current Liabilities amounts to 1.9m EUR.
What is Biotechnology Assets SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-34%
Over the last year, the Other Current Liabilities growth was 1%. The average annual Other Current Liabilities growth rates for Biotechnology Assets SA have been -13% over the past three years , -34% over the past five years .
You don't have any saved screeners yet
